Cargando…
SOSTDC1 inhibits bone metastasis in non-small cell lung cancer and may serve as a clinical therapeutic target
Bone metastasis occurs in ~40% patients with non-small cell lung cancer (NSCLC), resulting in serious morbidity and mortality. Sclerostin domain-containing protein 1 (SOSTDC1) has been demonstrated to be associated with the development and progression of multiple types of cancer. However, the role o...
Autores principales: | Chen, Guanghui, Gong, Haiyi, Wang, Ting, Wang, Jian, Han, Zhitao, Bai, Guangjian, Han, Shuai, Yang, Xinghai, Zhou, Wang, Liu, Tielong, Xiao, Jianru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202094/ https://www.ncbi.nlm.nih.gov/pubmed/30320379 http://dx.doi.org/10.3892/ijmm.2018.3926 |
Ejemplares similares
-
A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma
por: Zhao, Chenglong, et al.
Publicado: (2022) -
Biomechanical analysis of a novel height-adjustable nano-hydroxyapatite/polyamide-66 vertebral body: a finite element study
por: Chen, Guanghui, et al.
Publicado: (2019) -
Role of Sostdc1 in skeletal biology and cancer
por: Tong, Xiaoyang, et al.
Publicado: (2022) -
Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors
por: Blish, Kimberly R, et al.
Publicado: (2010) -
FMO family may serve as novel marker and potential therapeutic target for the peritoneal metastasis in gastric cancer
por: Gong, Xumeng, et al.
Publicado: (2023)